Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

Cited by (774)

Items 401–500 of 774

1. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors
   Wei‐Jan Huang, Ching‐Chow Chen, Shi-Wei Chao, Chia-Chun Yu, Chen‐Yui Yang, Jih‐Hwa Guh, Yun-Chieh Lin, Chiao-I Kuo, Ping Yang, Chung-I Chang · 2011 · European Journal of Medicinal Chemistry
2. Targeted therapy in acute myeloid leukaemia: current status and future directions
   Camilla Stapnes, Bjørn Tore Gjertsen, Håkon Reikvam, Øystein Bruserud · 2009 · Expert Opinion on Investigational Drugs
3. The unraveling of substrate specificity of histone deacetylase 6 domains using acetylome peptide microarrays and peptide libraries
   Zsófia Kutil, L. Skultetyova, David Rauh, Marat Meleshin, Ivan Šnajdr, Zora Nováková, Jana Mikesova, Jiřı́ Pavlı́ček, Martin Hadzima, Petra Baranová et al. · 2018 · The FASEB Journal
4. The Protein Farnesyltransferase Regulates HDAC6 Activity in a Microtubule-dependent Manner
   Jun Zhou, Chantal Chanel Vos, Ada Gjyrezi, Minoru Yoshida, Fadlo Raja Khuri, Fuyuhiko Tamanoi, Paraskevi Giannakakou · 2009 · Journal of Biological Chemistry
5. An HDAC6 inhibitor reverses chemotherapy-induced mechanical hypersensitivity via an IL-10 and macrophage dependent pathway
   Jixiang Zhang, Jiacheng Ma, Ronnie The Phong Trinh, Cobi J. Heijnen, Annemieke Kavelaars · 2021 · Brain Behavior and Immunity
6. Targeted therapies of gastrointestinal stromal tumors (GIST)—The next frontiers
   Stefan M. Duensing, Anette U. Duensing · 2010 · Biochemical Pharmacology
7. Sensitization of tumor cells by targeting histone deacetylases
   Paola Perego, Valentina Zuco, Laura Gatti, Franco Zunino · 2011 · Biochemical Pharmacology
8. Screening of selective histone deacetylase inhibitors by proteochemometric modeling
   Dingfeng Wu, Qi Huang, Yida Zhang, Qingchen Zhang, Qi Liu, Jun Alex Gao, Zhiwei Cao, Ruixin Zhu · 2012 · BMC Bioinformatics
9. Panobinostat for the treatment of multiple myeloma
   Paola E. Neri, Nizar Jacques Bahlis, Sagar Lonial · 2012 · Expert Opinion on Investigational Drugs
10. Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells
    Yi Liao, Xiaojia Niu, Bailing Chen, Holly J. Edwards, Liping Xu, Chengzhi Xie, Hai Lin, Lisa Polin, Jeffrey Warren Taub, Yubin Ge et al. · 2016 · Journal of Medicinal Chemistry
11. Novel Heat Shock Protein 90 Inhibitor NVP-AUY922 Synergizes With the Histone Deacetylase Inhibitor PXD101 in Induction of Death of Anaplastic Thyroid Carcinoma Cells
    Si Hyoung Kim, Jun Goo Kang, Chul Sik Kim, Sung‐Hee Ihm, Moon Gi Choi, Hyung Joon Yoo, Seong Jin Lee · 2014 · The Journal of Clinical Endocrinology & Metabolism
12. HDAC Inhibitor Modulation of Proteotoxicity as a Therapeutic Approach in Cancer
    David James McConkey, Matthew C. White, Wudan Yan · 2012 · Advances in cancer research
13. Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis
    Yvonne Eileen Klingl, Donya Pakravan, Ludo Van Den Bosch · 2020 · British Journal of Pharmacology
14. Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia
    Nina Reßing, Julian Schliehe‐Diecks, Paris R. Watson, Melf Sönnichsen, Abigail D. Cragin, Andrea Schöler, Jing Chun Yang, Linda Schäker‐Hübner, Arndt Borkhardt, David W. Christianson et al. · 2022 · Journal of Medicinal Chemistry
15. Orphan drug designation for pracinostat, volasertib and alvocidib in AML
    Prithviraj Bose, Steven Grant · 2014 · Leukemia Research
16. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL
    Jung Jin Hwang, Yong Sook Kim, Taelim Kim, Mi Joung Kim, In Gab Jeong, Je‐Hwan Lee, Jene Choi, Se-Jin Jang, Seonggu Ro, Choung‐Soo Kim · 2011 · Investigational New Drugs
17. Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells
    Silke Götze, Monique Coersmeyer, Oliver Müller, Sonja Sievers · 2014 · International Journal of Oncology
18. HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors
    Mikolaj Medon, Eva Vidacs, Stephin J. Vervoort, Jason Li, Misty Rayna Jenkins, Kelly M. Ramsbottom, Joseph A. Trapani, Mark John Smyth, Phillip Kevin Darcy, Peter Wisdom Atadja et al. · 2017 · Cancer Research
19. HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
    Teru Hideshima, Ralph Mazitschek, Jun Qi, Naoya Mimura, Jen‐Chieh Tseng, Andrew L. Kung, James E. Bradner, Kenneth Carl Anderson · 2017 · Oncotarget
20. Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells
    Sangkyu Park, Jeong-A Park, Hwanmin Yoo, Han-Bum Park, Younghee Lee · 2017 · Redox Biology
21. Simvastatin functions as a heat shock protein 90 inhibitor against triple‐negative breast cancer
    Xinhui Kou, Xiaoxiao Jiang, Huijuan Liu, Xuan Wang, Fanghui Sun, Jiami Han, Jiaxing Fan, Guize Feng, Zhaohu Lin, Lan Jiang et al. · 2018 · Cancer Science
22. HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?
    Hélène Losson, Michaël Schnekenburger, Mario A. Dicato, Marc F. Diederich · 2020 · Cancers
23. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells
    Si Hyoung Kim, Jun Goo Kang, Chul Sik Kim, Sung‐Hee Ihm, Moon Gi Choi, Hyung Joon Yoo, Seong Jin Lee · 2015 · Endocrine
24. Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives
    Nuggehally R. Srinivas · 2016 · Xenobiotica
25. Mc1568 Inhibits Hdac6/8 Activity and Influenza a Virus Replication in Lung Epithelial Cells: Role of Hsp90 Acetylation
    Simona Panella, Maria Elena Marcocci, Ignacio Celestino, Sérgio Valente, Clemens Zwergel, Domenica Donatella Li Puma, Lucia Nencioni, Antonello Mai, Anna Teresa Palamara, Giovanna Simonetti · 2016 · Future Medicinal Chemistry
26. HSP90: A Rising Star on the Horizon of Anticancer Targets
    Luke J. Whitesell, Chengkai Dai · 2005 · Future Oncology
27. Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90)
    Davide Bonanni, Andrea Citarella, Davide Moi, Luca Pinzi, Elisa Bergamini, Giulio Rastelli · 2021 · Current Medicinal Chemistry
28. S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability
    Niamh E. Buckley, Zenobia D’Costa, M Kaminska, Paul B. Mullan · 2014 · Cell Death and Disease
29. Differentially expressed genes and morphological changes during lengthened immobilization in rat soleus muscle
    Ji Won Kim, Oh Yun Kwon, Myoung Hee Kim · 2006 · Differentiation
30. Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress
    Ning Gao, Mohamed Rahmani, Xianglin Shi, Paul Dent, Steven Grant · 2005 · Blood
31. Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy
    Madhuri Sankaranarayanapillai, William P. Tong, David S. Maxwell, Ashutosh Pal, Jihai Pang, William G. Bornmann, Juri George Gelovani, Sabrina M. Ronen · 2006 · Molecular Cancer Therapeutics
32. ARDent about acetylation and deacetylation in hypoxia signalling
    Rebecca L. Bilton, Eric Trottier, Jacques Pouysségur, M. Christiane Brahimi-Horn · 2006 · Trends in Cell Biology
33. Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation
    Bohonowych, Jessica ES, Peng, Shuping, Gopal, Udhayakumar, Hance, Michael W, Wing, Shane B, Argraves, Kelley M, Lundgren, Karen, Isaacs, Jennifer S · 2011 · BMC Cancer
34. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors
    Sunil Sharma, Joachim Beck, Monica M Mita, Sofia Paul, Margaret M. Woo, Margaret K. T. Squier, Brian Gadbaw, Henry Miles Prince · 2013 · Investigational New Drugs
35. Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells
    Kazuo Kamemura, Akihiro Ito, Tadahiro Shimazu, Akihisa Matsuyama, Satoko Maeda, Tso‐Pang Yao, Sueharu Horinouchi, Saadi Khochbin, Minoru Yoshida · 2008 · Biochemical and Biophysical Research Communications
36. Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells
    Rui Wang, Ying Li, Ping Gong, Janice Lynn Gabrilove, Samuel Waxman, Yongkui Jing · 2018 · Molecular Cancer Therapeutics
37. Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms
    Brandi Reeves, Joan Denise Beckman · 2021 · Current Hematologic Malignancy Reports
38. Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma
    Raghupathy Vengoji, Pranita Atri, Muzafar Ahmad Macha, Parthasarathy Seshacharyulu, Naveenkumar Perumal, Kavita B. Mallya, Yutong Liu, Lynette M. Smith, Satyanarayana Rachagani, Sidharth Mahapatra et al. · 2021 · Journal of Experimental & Clinical Cancer Research
39. Targeting Huntington’s disease through histone deacetylases
    Steven G. Gray · 2011 · Clinical Epigenetics
40. Hydroxyurea increases eNOS protein levels through inhibition of proteasome activity
    Vladan P. Čokić, Bojana B. Beleslin‐Čokić, Constance Tom Noguchi, Alan N. Schechter · 2007 · Nitric Oxide
41. SOX8 Regulates Permeability of the Blood-Testes Barrier That Affects Adult Male Fertility in the Mouse1
    Ajeet Pratap Singh, Connie A. Cummings, Yuji M. Mishina, Trevor Archer · 2013 · Biology of Reproduction
42. Flavones and flavonols may have clinical potential as CK2 inhibitors in cancer therapy
    Mark Frederick McCarty, Simon Bernard Iloki Assanga, Lidianys María Lewis Luján · 2020 · Medical Hypotheses
43. Monitoring Histone Deacetylase Inhibition In Vivo: Noninvasive Magnetic Resonance Spectroscopy Method
    Madhuri Sankaranarayanapillai, William P. Tong, Qing Yuan, James A. Bankson, Hagit Dafni, William G. Bornmann, Suren Soghomonyan, Ashutosh Pal, Marc S. Ramirez, Douglas Webb et al. · 2008 · Molecular Imaging
44. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms
    Prithviraj Bose, Srđan Verstovšek · 2016 · Expert Opinion on Investigational Drugs
45. HDAC6 and Ovarian Cancer
    Joshua Haakenson, Xiaohong Mary Zhang · 2013 · International Journal of Molecular Sciences
46. Rational Combinations of Targeted Agents in AML
    Prithviraj Bose, Steven Grant · 2015 · Journal of Clinical Medicine
47. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
    David Samuel DiCapua Siegel, Meletios Athanasios Dimopoulos, Sundar Jagannath, Hartmut Goldschmidt, Simon Durrant, Jonathan L. Kaufman, Xavier P Leleu, Arnon Nagler, Fritz C. Offner, Thorsten T. Graef et al. · 2016 · Clinical Lymphoma Myeloma & Leukemia
48. Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis
    Amir Zeb, Chanin Park, Shailima DV Rampogu, Minky Son, Gihwan Lee, Keun Woo Lee · 2018 · ACS Chemical Neuroscience
49. Heat-Shock Proteins in Leukemia and Lymphoma: Multitargets for Innovative Therapeutic Approaches
    Vincent Cabaud Gibouin, Manon Durand, Ronan Quéré, François Girodon, Carmen Garrido, Gaëtan Jégo · 2023 · Cancers
50. Efficacy of Histone Deacetylase and Estrogen Receptor Inhibition in Breast Cancer Cells Due to Concerted down Regulation of Akt
    Scott Thomas, Kenneth T. Thurn, Paromita Raha, Stephanie Chen, Pamela N. Münster · 2013 · PLoS ONE
51. Differential effects of binge methamphetamine injections on the mRNA expression of histone deacetylases (HDACs) in the rat striatum
    Oluwaseyi Omonijo, Pawaris Wongprayoon, Bruce Ladenheim, Michael T. McCoy, Piyarat Govitrapong, Subramaniam Jayanthi, Jean Lud Cadet · 2014 · NeuroToxicology
52. The Role of Alcohol-Induced Golgi Fragmentation for Androgen Receptor Signaling in Prostate Cancer
    Sonia Manca, Cole P. Frisbie, Chad A. LaGrange, Carol A. Casey, Jean-Jack M. Riethoven, Armen Petrosyan · 2018 · Molecular Cancer Research
53. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin’s lymphoma
    Susmitha Apuri, Lubomir Sokol · 2016 · Expert Opinion on Investigational Drugs
54. The HDAC6 Inhibitor Tubacin Induces Release of CD133+ Extracellular Vesicles From Cancer Cells
    Olivia S. Chao, Tim C. Chang, Maria Antonietta Di Bella, Riccardo Alessandro, Fabio Anzanello, Germana Rappa, Oscar B. Goodman, Aurelio Lorico · 2017 · Journal of Cellular Biochemistry
55. PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ
    Masami Iwasa, Takeshi Harada, Asuka Oda, Ariunzaya Bat‐Erdene, Jumpei Teramachi, Hirofumi Tenshin, Mohannad Ashtar, Masahiro Oura, Kimiko Sogabe, Kengo Udaka et al. · 2019 · Oncotarget
56. Modulation of serine/threonine-protein phosphatase 1 (PP1) complexes: A promising approach in cancer treatment
    Bárbara Matos, John Howl, Cármen Jerónimo, Margarida Fardilha · 2021 · Drug Discovery Today
57. Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases
    Jianglei Li, Meihong Yu, Shifeng Fu, Deliang Liu, Yuyong Tan · 2022 · Frontiers in Pharmacology
58. Depression of mitochondrial metabolism by downregulation of cytoplasmic deacetylase, HDAC6
    Kazuo Kamemura, Mitsutaka Ogawa, Saki Ohkubo, Yasuhiro Ohtsuka, Yu Shitara, Tohru Komiya, Satoko Maeda, Akihiro Ito, Minoru Yoshida · 2012 · FEBS Letters
59. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells
    Akinori Sato, Takako Asano, Makoto Isono, Keiichi Ito, Tomohiko Asano · 2014 · BMC Urology
60. Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1
    Hak-Bong Kim, Su-Hoon Lee, Jee‐Hyun Um, Won Keun Oh, Dong-Wan Kim, Chi‐Dug Kang, Sun‐Hee Kim · 2015 · Oncotarget
61. Panobinostat for the treatment of acute myelogenous leukemia
    Fortunato Morabito, Maria Teresa Voso, Stefan Hohaus, Massimo Gentile, Ernesto Vigna, Anna Grazia Recchia, Lorenzo Iovino, E. Benedetti, Francesco Lo‐Coco, Sara Galimberti · 2016 · Expert Opinion on Investigational Drugs
62. Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and Tubulin in Hormone Refractory Prostate Cancer Cells
    Jung Jin Hwang, Yong Sook Kim, Mi Joung Kim, Dong‐Eun Kim, In Gab Jeong, Choung‐Soo Kim · 2010 · The Journal of Urology
63. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically
    Akinori Sato, Takako Asano, Keiichi Ito, Makoto Sumitomo, Tomohiko Asano · 2011 · British Journal of Urology
64. Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer
    Sophia N. Ononye, Michael van Heyst, Eric M Falcone, A. Anderson, D. Wright · 2012 · Pharmaceutical Patent Analyst
65. Ritonavir Interacts With Bortezomib to Enhance Protein Ubiquitination and Histone Acetylation Synergistically in Renal Cancer Cells
    Akinori Sato, Takako Asano, Keiichi Ito, Tomohiko Asano · 2012 · Urology
66. Abrogation of Mitogen-Activated Protein Kinase and Akt Signaling by Vandetanib Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis in Human Glioma Cells
    Esther P. Jane, Daniel R. Premkumar, Steven O. Addo‐Yobo, Ian F. Pollack · 2009 · Journal of Pharmacology and Experimental Therapeutics
67. AKT activation controls cell survival in response to HDAC6 inhibition
    Maciej A. Kaliszczak, Sebastian Trousil, T Ali, Eric Ofori Aboagye · 2016 · Cell Death and Disease
68. Comparative Proteomic Analysis of Chronic Myelogenous Leukemia Cells: Inside the Mechanism of Imatinib Resistance
    Germano Ferrari, Roberta Pastorelli, Francesca Buchi, Elena Spinelli, Antonella Gozzini, Alberto Bosi, Valeria Santini · 2006 · Journal of Proteome Research
69. Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
    Elizabeth K. Lee, Zhenying Tan‐Wasielewski, Ursula A. Matulonis, Michael J. Birrer, Alexi A. Wright, Neil Stuart Horowitz, Panagiotis A. Konstantinopoulos, Jennifer D. Curtis, Joyce F. Liu · 2019 · Gynecologic Oncology Reports
70. Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: New chances for sophisticated drug design and treatment optimization
    Bernhard Biersack, Bianca Nitzsche, Michael Höpfner · 2022 · Seminars in Cell and Developmental Biology
71. Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human Mantle Cell Lymphoma (MCL) cells
    Rekha Rao, Pearl Lee, Warren C. Fiskus, Yonghua Yang, Rajeshree Joshi, Yongchao Wang, Kate Buckley, Ramesh Balusu, Jianguang Chen, Sanjay Koul et al. · 2009 · Cancer Biology & Therapy
72. Histone deacetylase (HDAC) 4 involvement in both Lewy and Marinesco bodies
    Junko Takahashi‐Fujigasaki, Hiroto Fujigasaki · 2006 · Neuropathology and Applied Neurobiology
73. STAT5 acetylation
    Christian Kosan, Torsten Ginter, Thorsten Heinzel, Oliver Holger Krämer · 2013 · JAK-STAT
74. The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV‐infected patients on suppressive antiretroviral therapy
    J H Li, Jing Ma, W Kang, C F Wang, F Bai, Keke Zhao, N Yao, Q Liu, BL Dang, BW Wang et al. · 2020 · HIV Medicine
75. Down‐regulation of Thanatos‐associated protein 11 by BCR‐ABL promotes CML cell proliferation through c‐Myc expression
    Satoki Nakamura, Daisuke Yokota, Lin Tan, Yasuyuki Nagata, Tomonari Takemura, Isao Hirano, Kazuyuki Shigeno, Kiyoshi Shibata, Shinya Fujisawa, Kazunori Ohnishi · 2011 · International Journal of Cancer
76. Metformin Augments Panobinostat's Anti-Bladder Cancer Activity by Activating AMP-Activated Protein Kinase
    Kazuki Okubo, Makoto Isono, Takako Asano, Akinori Sato · 2019 · Translational Oncology
77. Ubiquitin B: an essential mediator of trichostatin A-induced tumor-selective killing in human cancer cells
    Peng Wu, Ye Edward Tian, G Chen, Bingbao Wang, Lingli Gui, L Xi, Xiangyi Ma, Yong Fang, Tao Zhu, Dejuan Wang et al. · 2009 · Cell Death and Differentiation
78. Beyond JAK inhibitor therapy in myelofibrosis
    Olatoyosi M. Odenike · 2013 · Hematology
79. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis
    Prithviraj Bose, Mahesh Swaminathan, Naveen Pemmaraju, Alessandra Ferrajoli, Elias Joseph Jabbour, Naval Guastad Daver, Courtney Denton Dinardo, Yesid Alvarado, Musa E. Yilmaz, Julie Huynh-Lu et al. · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
80. HDAC6 Inhibition Reverses Cisplatin-Induced Mechanical Hypersensitivity via Tonic Delta Opioid Receptor Signaling
    Jixiang Zhang, Jazzmine M. Junigan, Ronnie The Phong Trinh, Annemieke Kavelaars, Cobi J. Heijnen, Peter M. Grace · 2022 · Journal of Neuroscience
81. The role of viruses in cancer development versus cancer therapy: An oncological perspective
    Hossein Javid, Alireza Sharbaf Mashhad, Shaghayegh Yazdani, Mahsa Akbari Oryani, Sanaz Akbari, Nastaran Rezagholinejad, Mahboubeh Tajaldini, Mehdi Karimi‐Shahri · 2023 · Cancer Medicine
82. Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage
    Sangkyu Park, Jeong-A Park, Jae-Hyung Jeon, Younghee Lee · 2019 · Biomolecules & Therapeutics
83. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer
    Peter M. Wilson, Melissa J. LaBonte, Shelby C. Martin, Stephanie T Kuwahara, Anthony B. El-Khoueiry, Heinz‐Josef Lenz, Robert D. Ladner · 2013 · Investigational New Drugs
84. Histone Deacetylase 6–Controlled Hsp90 Acetylation Significantly Alters Mineralocorticoid Receptor Subcellular Dynamics But Not its Transcriptional Activity
    Rubén Jiménez-Canino, Fabián Lorenzo-Díaz, Frédéric Jaisser, Nicolette Farman, Teresa Giráldez, Diego Álvarez de la Rosa · 2016 · Endocrinology
85. Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups
    Gustavo Salgado Pires, Heber Victor Tolomeu, Daniel Alencar Rodrigues, Lı́dia Moreira Lima, Carlos Alberto Manssour Fraga, Pedro de Sena Murteira Pinheiro · 2025 · Pharmaceuticals
86. C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
    Sivakami Mylvaganam, Rebecca Earnshaw, Gregory Heymann, Suneil Kumar Kalia, Lorraine V. Kalia · 2020 · Current Neuropharmacology
87. Therapy of Relapsed and Refractory Multiple Myeloma
    Thomas M. Moehler, Hartmut Goldschmidt · 2011 · Recent results in cancer research/Recent Results in Cancer Research
88. Novel Combination Treatments Targeting Chronic Myeloid Leukemia Stem Cells
    Tareq Al Baghdadi, Rafat Abonour, H. Scott Boswell · 2011 · Clinical Lymphoma Myeloma & Leukemia
89. Novel therapies in MM: from the aspect of preclinical studies
    Teru Hideshima, Kenneth Carl Anderson · 2011 · International Journal of Hematology
90. Critical review of non‐histone human substrates of metal‐dependent lysine deacetylases
    Tasha B. Toro, Terry J. Watt · 2020 · The FASEB Journal
91. Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation
    Akinori Sato, Takako Asano, Kazuki Okubo, Makoto Isono, Tomohiko Asano · 2017 · Cancer Science
92. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
    Bailin He, Qiang Wang, Xiaoli Liu, Ziyuan Lu, Jiaochan Han, Chengyun Pan, Bing Z. Carter, Qifa Liu, Na Xu, Hongsheng Zhou · 2020 · Biomedicine & Pharmacotherapy
93. Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors
    Hao Hu, Fei Chen, Yuhong Dong, Ming Li, Sicong Xu, Mingze Qin, Ping Gong · 2020 · European Journal of Medicinal Chemistry
94. Synthesis of 2-(1 H -Indol-2-yl)acetamides via Brønsted Acid-Assisted Cyclization Cascade
    Nicolai A. Aksenov, Дмитрий А. Аксенов, Anton A. Skomorokhov, Lidiya A. Prityko, Alexander V. Aksenov, Георгий Д. Грязнов, Michael Rubin · 2020 · The Journal of Organic Chemistry
95. RETRACTED: P210 Bcr‐abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors
    Gianluca Brusa, Elisa Zuffa, Manuela Mancini, Michela Benvenuti, Natalia Calonghi, Enza Barbieri, Maria Alessandra Santucci · 2005 · British Journal of Haematology · Retracted
96. Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase
    Pascale Flandrin‐Gresta, Françoise Solly, Carmen Mariana Aanei, Jérôme Cornillon, Emmanuelle Tavernier, Nathalie Nadal, Franck Morteux, Denis Guyotat, Eric Wattel, Lydia Campos · 2012 · Oncotarget
97. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
    Faria Sultana, Kesari Lakshmi Manasa, Siddiq Pasha Shaik, Srinivasa Reddy Bonam, Ähmed Kamal · 2018 · Current Medicinal Chemistry
98. Lysine Acetylation is an Important Post-Translational Modification that Modulates Heat Shock Response in the Sea Cucumber Apostichopus japonicus
    Dongxue Xu, Xuan Wang · 2019 · International Journal of Molecular Sciences
99. A New Histone Deacetylase Inhibitor Enhances Radiation Sensitivity through the Induction of Misfolded Protein Aggregation and Autophagy in Triple-Negative Breast Cancer
    Hui‐Wen Chiu, Ya-Ling Yeh, Sheng‐Yow Ho, Yuan-Hua Wu, Bour-Jr Wang, Wei‐Jan Huang, Yuan‐Soon Ho, Ying‐Jan Wang, Li-Ching Chen, Shih‐Hsin Tu · 2019 · Cancers
100. Impact of IL-15 and latency reversing agent combinations in the reactivation and NK cell-mediated suppression of the HIV reservoir
     D. Covino, M. Desimio, M. Doria · 2022 · Scientific Reports